MV Chandrakanth: TALAPRO-3 Reports a 52% Reduction in Progression Risk

Coverage, in order

1. 3d ago
   
   OncoDaily obscure study peer-reviewed

   MV Chandrakanth: TALAPRO-3 Reports a 52% Reduction in Progression Risk

   MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X: “TALAPRO-3 / 52% less progression – but at what cost? NEJM 2026 / The Upfront vs Sequential PARP Debate

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.